Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
8/7, MoneyTV with Donald Baillargeon
Date : 08/07/2009 @ 5:00AM
Source : MarketWire
http://ih.advfn.com/p.php?pid=nmona&cb=1249636179&article=38951001&symbol=NB^CBAI
LOS ANGELES, CA -- (Marketwire) -- 08/07/09 -- Bioterrorism detection, stem cell storage lab, "Dead of Night" movie and mortgage advice; this week on MoneyTV, hosted by anchor Donald Baillargeon. MoneyTV is the internationally syndicated television program all about money and what makes it happen, (http://www.moneytv.net), featuring informative interviews with company CEOs, providing insights into their operations and outlooks for their futures.
Free information packages from the featured companies can be requested by sending an email to info@moneytv.net.
The television program can also be viewed online immediately at www.moneytv.net.
Featured companies on this week's program include:
Cord Blood America, Inc. (OTCBB: CBAI) CEO Matthew Schissler talked about the company's new laboratory in Las Vegas, scheduled to go online in October.
! removed ASYTQ from "Chapter 11 - P(Q)LI"-section !
JGBO - Chart
Jiangbo Pharmaceuticals, Inc.(US office)
Ms. Elsa Sung, Chief Financial Officer,
950 S.Pine Island Road,
Suite A-150 Plantation,
Florida 33324
Telephone: (954) 727-8436
Fax: (954) 727-8448
Email:General Information: jiangbopharma@gmail.com
Investor relations: crocker.coulson@ccgir.com
Address of Factory in China:
25 Haihe Road,
Laiyang Development Zone,
Laiyang City,Yantai,
Shandong,China 265200
Raser Technologies Announces Second Quarter Financial Results
Date : 08/06/2009 @ 4:23PM
Source : Business Wire
http://ih.advfn.com/p.php?pid=nmona&cb=1249620829&article=38945301&symbol=NY^RZ
SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights
Date : 08/06/2009 @ 4:01PM
Source : PR Newswire
http://ih.advfn.com/p.php?pid=nmona&cb=1249620829&article=38944903&symbol=N^SQNM
SEQUENOM, Inc. Q2 2009 Earnings Call Transcript
August 06, 2009
http://seekingalpha.com/article/154518-sequenom-inc-q2-2009-earnings-call-transcript?source=feed
...newest 0815ax-pick
http://www.finviz.com/quote.ashx?t=MPG&ty=c&ta=0&p=d
http://www.shortsqueeze.com/?symbol=mpg&submit=Short+Quote%99
Shares Float 29,840,000
Total Shares Outstanding 47,981,347
% Owned by Insiders 22.22 %
% Owned by Institutions 67.30 %
http://biz.yahoo.com/cc/7/106797.html
Maguire Properties to Release Second Quarter 2009 Financial Results on August 10, 2009
* Press Release
* Source: Maguire Properties, Inc.
* On Wednesday August 5, 2009, 9:08 pm EDT
Quarterly Report (10-Q) - For the quarterly period ended June 30, 2009
Date : 08/04/2009 @ 6:26AM
Source : Edgar (US Regulatory)
http://ih.advfn.com/p.php?pid=nmona&cb=1249575204&article=38893299&symbol=NY^PLD
Vonage: Can it Grow Customer Base?
by: Larry Dignan August 06, 2009
http://seekingalpha.com/article/154325-vonage-can-it-grow-customer-base?source=feed
EMCORE Corporation to Report Fiscal 2009 Third Quarter Results on Monday, August 17, 2009
Date : 08/06/2009 @ 11:26AM
Source : MarketWire
http://ih.advfn.com/p.php?pid=nmona&cb=1249574356&article=38940494&symbol=N^EMKR
ALBUQUERQUE, NM -- (Marketwire) -- 08/06/09 -- EMCORE Corporation (NASDAQ: EMKR), a leading provider of compound semiconductor-based components and subsystems for the fiber optics and solar power markets, will announce its fiscal 2009 third quarter results for the period ended June 30, 2009 on Monday, August 17, 2009 after market close. A conference call discussing the results will follow at 5:00 p.m. ET.
Conference Call Information:
To participate in the conference call, U.S. callers should dial 800-930-1344 and international callers should dial 913-312-0847. The access code for the call is 4504248. A replay of the call will be available beginning August 17, 2009 at 8:30 p.m. ET until August 24, 2009 at 11:59 p.m. ET. The replay call-in number for U.S. callers is 888-203-1112 and is 719-457-0820 for international callers. The access code is 4504248. The conference call also will be web cast via the Company's web site at http://www.emcore.com. Please go to the site beforehand to download any necessary software.
Sunrise Reports Financial Results for Second-Quarter 2009
Date : 08/06/2009 @ 7:00AM
Source : PR Newswire
http://ih.advfn.com/p.php?pid=nmona&cb=1249563135&article=38934069&symbol=NY^SRZ
2009 DIVIDENDS
http://ih.advfn.com/p.php?pid=nmona&cb=1249557308&article=38906956&symbol=N^ACAS
On July 31, 2009, American Capital announced the results of its stockholders' elections relating to the Company's dividend previously declared by its Board of Directors on June 11, 2009. The dividend of $1.07 per share is payable on August 7, 2009 to stockholders of record as of the close of business on June 22, 2009, with an ex-dividend date of June 18, 2009. Stockholders had until July 24, 2009 to elect whether to receive the dividend in cash (up to an aggregate maximum of 10% of the total dividend paid) or in shares of common stock. Due to the original terms of the dividend, stockholders who elected to receive cash will receive a combination of cash and common stock.
Based on stockholder elections and the price of American Capital's common stock, the dividend will consist of approximately $24 million in cash and approximately 67 million shares of common stock. The amount of cash elected to be received was greater than the cash limit of 10% of the aggregate dividend amount, and therefore stockholders who elected to receive all cash will receive a combination of cash and stock. Stockholders electing to receive the dividend in all cash, will receive cash in the amount of $0.185 per share or 17% of the $1.07 dividend and 0.275 shares of common stock or 83% of the total dividend for each share of common stock they owned on the record date. The number of shares of common stock comprising the stock portion was calculated based on a price of $3.2199 per share, the average of the volume weighted trading price per share on the NASDAQ Global Select Market on July 27, 28 and 29, 2009.
US Earnings Calendar for August 6, 2009
http://biz.yahoo.com/research/earncal/20090806.html?t=sqnm
Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval
Total Net Operating Expenses Decrease Significantly in First Half 2009 Compared to First Half 2008
* Press Release
* Source: Cell Therapeutics, Inc.
* On Thursday August 6, 2009, 1:30 am EDT
http://finance.yahoo.com/news/Cell-Therapeutics-Second-prnews-2649751517.html?x=0&.v=1
SEATTLE, Aug. 6 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) today reported recent achievements and financial results for the second quarter and six months ended June 30, 2009.
"The second quarter of 2009 was a transforming quarter for the Company as we reported, in a peer reviewed setting, pixantrone phase III data at the American Society of Clinical Oncology Annual Meeting and completed the submission of the pixantrone New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA)," said James A. Bianco, M.D., CEO of Cell Therapeutics. "On the financial front, we continue to reduce and control our operating expenses, eliminated 44.5% of our outstanding debt through exchange offers completed in June 2009, and raised significant capital to continue to advance pixantrone to market."
Recent Highlights
* Completed the submission of the pixantrone NDA to the FDA to treat relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL). CTI requested priority review of the pixantrone NDA which, if granted, could lead to an approval decision from the FDA in the fourth quarter of 2009.
* Reduced outstanding debt by $52.9 million, representing 44.5% of outstanding debt, through exchange offers completed in June 2009, resulting in an estimated savings in future annual interest expense of approximately $3.3 million.
* Added to the Russell 3000®, Russell 2000® and Russell Global® Indexes.
* Raised $43.8 million in gross proceeds in connection with financing transactions in the second quarter of 2009, and an additional $41.7 million in proceeds, net of underwriting discount, in connection with an underwritten offering of common stock and warrants in July 2009.
For the quarter ended June 30, 2009, total net operating expenses decreased approximately 24% to $21.7 million, compared to $28.7 million for the same period in 2008. The decrease is mainly a result of a 54% reduction in research and development expenses for the quarter ended June 30, 2009, compared to the same period in 2008. Total operating expenses included restructuring charges of $3.8 million related to the closing of CTI's Bresso, Italy research facility. Net loss attributable to common shareholders decreased by 54% to $27.4 million ($0.06 per share), compared to a net loss attributable to common shareholders of $59.3 million ($5.18 per share) for the same period in 2008. The reduction in net loss per share is due to an increase in the number of shares outstanding and a reduction in research and development and financing expenses as described above.
For the six months ended June, 30 2009, total operating expenses decreased approximately 50% to $28.3 million, compared to $57.0 million for the same period in 2008. The decrease is mainly a result of a 52% decrease in research and development expenses and a $10.2 million gain on the sale of CTI's remaining interest in a 50/50-owned joint venture with Spectrum Pharmaceuticals, Inc. in 2009. Net loss attributable to common shareholders decreased 64% to $40.6 million ($0.11 per share), compared to a net loss attributable to common shareholders of $113.9 million ($12.28 per share) for the same period in 2008. The reduction in net loss per share is due to an increase in the number of shares outstanding and a reduction in research and development and financing as described above.
CTI had approximately $12.0 million in cash and cash equivalents, securities available-for-sale, and interest receivable as of June 30, 2009. This does not include approximately $41.7 million, net of underwriting discount, the Company received in July 2009 in connection with an underwritten offering of common stock and warrants.
Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
Date : 08/05/2009 @ 4:45PM
Source : PR Newswire
http://ih.advfn.com/p.php?pid=nmona&cb=1249555927&article=38925490&symbol=N^KERX
Keryx to Host Investor Conference Call on Thursday, August 6, 2009 at 8:30am EDT
NEW YORK, Aug. 5 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer (the "Company"), today announced its results for the second quarter ended June 30, 2009.
At June 30, 2009, the Company had cash, cash equivalents, short-term investment securities and interest receivable of $13.4 million, as compared to $15.5 million at December 31, 2008. In addition, at June 30, 2009, the Company had $7.1 million of auction rate securities which are classified as long-term investments. Additionally, in July 2009, the Company received $2.75 million of cash from a settlement with the former licensor of Sulonex (sulodexide). The Company will receive an additional $750,000 on or before July 30, 2010 related to this settlement.
The net income for the second quarter ended June 30, 2009 was $14.1 million, or $0.29 per diluted share, compared to a net loss of $7.7 million, or $0.17 per share, for the second quarter in 2008. The change in net income (loss) was primarily attributable to the recognition of $18.0 million in license revenue relating to an amendment to the September 2007 sublicense agreement with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. (JT/Torii), which eliminated the Company's significant ongoing obligations included in the original agreement, a $1.8 million decrease in research and development expenses related to KRX-0401, and a $1.0 million decrease in research and development expenses related to the cessation of the development of Sulonex in March 2008.
The net income for the six months ended June 30, 2009 was $14.6 million, or $0.30 per diluted share, compared to a net loss of $42.2 million, or $0.96 per share, for the comparable period in 2008. The change in net income (loss) was primarily attributable to a $26.9 million decrease in research and development expenses related to the cessation of the development of Sulonex in March 2008, a $4.4 million decrease in research and development expenses related to KRX-0401, and a $21.1 million increase in license revenue related to an amendment to the September 2007 sublicense agreement with JT/Torii ($18.0 million), as discussed above, and a $3.0 million milestone payment from JT/Torii earned in the first quarter of 2009.
Commenting on the quarter, Ron Bentsur, the Company's Chief Executive Officer, remarked, "Keryx has made significant progress over the last few months. We presented important Phase 2 data on both our compounds, regained full compliance with the listing requirements of the Nasdaq Capital Market, and announced our SPA for the Phase 3 trial of perifosine in multiple myeloma. We look forward to finalizing our discussions with the FDA regarding the U.S. Phase 3 program for Zerenex shortly, at which time Keryx will be in the compelling position of having two Phase 3 compounds." Mr. Bentsur added, "I am excited by the opportunity to transform Keryx into a late-stage development company and maximize shareholder value. On behalf of the entire Keryx team, I want to thank all of our shareholders for their continued support."
On Thursday, August 6, 2009, at 8:30am EDT, the Company will host an investor conference call during which they will provide a brief financial overview of the Company's second quarter financial results and a business outlook for the remainder of 2009.
In order to participate in the conference call, please call 1-877-869-3847 (U.S.), 1-201-689-8261 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com/, for a period of 15 days after the call.
Vonage Holdings Corp. Q2 2009 Earnings Call Transcript
August 05, 2009
http://seekingalpha.com/article/154051-vonage-holdings-corp-q2-2009-earnings-call-transcript?source=feed
Suntech Signs Contract with Recurrent Energy to Deliver 5MW of Modules in Q4 2009 for California's Largest Solar Photovoltaic System
Date : 08/05/2009 @ 8:00AM
Source : PR Newswire
http://ih.advfn.com/p.php?pid=nmona&cb=1249500516&article=38914702&symbol=NY^STP
SAN FRANCISCO, Aug. 5 /PRNewswire-Asia/ -- Suntech Power Holdings Co., Ltd. (NYSE:STP), the world's largest crystalline silicon photovoltaic (PV) module manufacturer, announced today that it has been selected to supply over 25,000 modules for Recurrent Energy's five megawatt municipal solar power project atop the Sunset Reservoir in San Francisco, California. All modules are scheduled for delivery in the fourth quarter of 2009.
The project, contracted by the San Francisco Public Utilities Commission in late 2008 and signed into law by San Francisco Mayor Gavin Newsom in May 2009, will more than triple San Francisco's total municipal solar power output from 2MW today to 7MW upon completion in 2010. According to the SFPUC, it will be California's largest solar photovoltaic (PV) system to date.
'Suntech America and Recurrent Energy are both San Francisco-based companies and we are proud to jointly participate in bringing a green energy future to this wonderful city,' said Steven Chan, Suntech's Chief Strategy Officer and President, Global Sales/Marketing. 'Working together, we can help reduce dependence on fossil fuels throughout North America. Forward-thinking projects such as the Sunset Reservoir system set a notable precedent for reducing greenhouse gases and stimulating a national green economy.'
After extensive vetting, Recurrent Energy chose Suntech's high-efficiency solar modules to help maximize energy production after considering the site's urban setting and finite usable roof space. Suntech modules are effective in converting the sun's rays into electricity in low and indirect light, an important factor given the site's wide variety of weather conditions during the year.
'The combination of the system design and Suntech modules will help us to deliver the maximum amount of solar energy and environmental benefits over the lifetime of the Sunset Reservoir project,' said Arno Harris, CEO of Recurrent Energy. 'This PV system is expected to produce enough renewable energy to provide for 1,000 typical City residents, avoiding the release of more than 109,000 metric tons of carbon dioxide emissions.'
Recurrent Energy will own and operate the system and sell all the renewable electricity to the City and County of San Francisco under a 25-year power purchase agreement. The anticipated production for the 5 MW project is 6,560,000 kWh in the first year. Under the agreement, Recurrent Energy assumes all financing, construction, and operating obligations for the project.
About Recurrent Energy
Recurrent Energy is a distributed power company and a leading provider of solar energy. The company solves rising global demand for clean energy by developing and owning solar power plants located in areas of high demand where power is needed most. Recurrent Energy sells clean electricity to commercial, government, and utility customers at competitive rates via Power Purchase Agreements or Feed-in Tariffs. Notable projects include a 5 megawatt planned installation with The City and County of San Francisco, which will be the largest municipal solar installation in the United States upon completion. For more information on Recurrent Energy and distributed solar power, please visit http://www.recurrentenergy.com/ .
About Suntech
Suntech Power Holdings Co., Ltd. (NYSE:STP) is the world's leading solar energy company as measured by production output of crystalline silicon solar modules. Suntech designs, develops, manufactures, and markets premium quality, high-output, cost-effective and environmentally friendly solar products for electric power applications in the residential, commercial, industrial, and public utility sectors. Suntech's patent-pending Pluto technology for crystalline silicon solar cells improves power output by up to 12% compared to conventional production methods. Suntech also offers one of the broadest ranges of building-integrated solar products under the MSK Solar Design Line(TM).
Suntech designs and delivers commercial and utility scale solar power systems through its wholly owned subsidiary Suntech Energy Engineering and will own and operate projects greater than 10 megawatts in the United States through Gemini Solar Development Company, a joint venture with Renewable Ventures, a Fotowatio company. With regional headquarters in China, Switzerland and San Francisco and sales offices worldwide, Suntech is passionate about improving the environment we live in and dedicated to developing advanced solar solutions that enable sustainable development. For more information, please visit http://www.suntech-power.com/ .
Staffing Firms to See Increased Demand for Health Care, Technical and Contract Work in Third Quarter, Finds CareerBuilder's Staff
Date : 08/05/2009 @ 3:06PM
Source : PR Newswire
http://ih.advfn.com/p.php?pid=nmona&cb=1249500516&article=38923849&symbol=NY^GCI
Mirion Technologies Awarded Contract to Supply Radiation Monitoring Systems to Ten Chinese Nuclear Power Plants
Date : 08/05/2009 @ 1:00PM
Source : Business Wire
http://ih.advfn.com/p.php?pid=nmona&cb=1249498922&article=38921211&symbol=N^ACAS
The Mirion Technologies’ Radiation Monitoring Systems (RMS) Division today announced that it has been awarded a contract to supply radiation monitoring systems for 10 new nuclear power plants to be built in China by China Nuclear Power Engineering Company Ltd (CNPEC).
The nuclear power plants will follow the Chinese CPR1000 design and will be located at the Hongyanhe site in Liaoning province, the Ningde site in Fujian province and the Yangjiang site in Guangdong province. The contract award encompasses 10 complete sets of radiation monitoring systems anticipated to be delivered between 2011 and 2013.
Under the contract award, the RMS Division will deliver a full suite of radiation monitoring systems to each CPR1000, including those related to Barrier Leak Control, Effluent Release Monitoring, Process Operations, Post-Accident Management and Radioprotection of Workers. The project covers design, engineering, manufacturing, commissioning and training of all the systems, including several safety-related monitors.
“We are delighted our client has selected us for this contract, which represents one of the largest ever received by Mirion Technologies,” commented Jean-Louis Gouronc, President of Mirion’s RMS Division. “It is reflective of our long-term presence in the Chinese nuclear power market. We look forward to delivering this project over the coming years and continuing to develop our relationships in this important market.”
ABOUT MIRION TECHNOLOGIES
Mirion Technologies is a world leader in radiation detection, measuring and monitoring. Mirion has facilities in Europe, Asia, and North America. Mirion Technologies is headquartered in the San Francisco Bay area and is a portfolio company of American Capital (NASDAQ:ACAS).
ACAS (2) -
Mirion Technologies Awarded Contract to Supply Radiation Monitoring Systems to Ten Chinese Nuclear Power Plants
Date : 08/05/2009 @ 1:00PM
Source : Business Wire
http://ih.advfn.com/p.php?pid=nmona&cb=1249498922&article=38921211&symbol=N^ACAS
ACAS (1) -
American Capital Announces Q2 2009 Results
Date : 08/04/2009 @ 7:30PM
Source : PR Newswire
http://ih.advfn.com/p.php?pid=nmona&cb=1249498922&article=38906956&symbol=N^ACAS
American Capital falls on Q2 loss,still in default
Aug 5 (Reuters)
http://www.finanznachrichten.de/nachrichten-2009-08/14617061-american-capital-falls-on-q2-loss-still-in-default-020.htm
ProLogis upgraded
http://www.newratings.com/en/main/company_headline.m?id=1943103
NEW YORK, July 24 (newratings.com) - Analysts at JP Morgan upgrade ProLogis (PLD) from "underweight" to "neutral."
ProLogis Declares Dividend on Common Shares
http://www.finanznachrichten.de/nachrichten-2009-08/14594727-prologis-declares-dividend-on-common-shares-008.htm
DENVER, Aug. 3 /PRNewswire-FirstCall/ -- ProLogis , a leading global provider of distribution facilities, announced today that its Board declared ProLogis' third quarter dividend of $0.15 per common share, payable on August 31, 2009, to shareholders of record on August 14, 2009.
About ProLogis
ProLogis is a leading global provider of distribution facilities, with more than 475 million square feet of industrial space owned and managed (44 million square meters) in markets across North America, Europe and Asia. The company leases its industrial facilities to more than 4,500 customers, including manufacturers, retailers, transportation companies, third-party logistics providers and other enterprises with large-scale distribution needs. For additional information about the company, go to http://www.prologis.com/.
ProLogis Declares Dividend
August 05, 2009
http://www.zacks.com/stock/news/23246/ProLogis+Declares+Dividend
ProLogis (PLD - Analyst Report), one of the leading global providers of distribution facilities, recently declared a third-quarter dividend of $0.15 per share.
The company had previously reduced its annual dividend payout to $0.70 per share from $1.00 declared earlier, significantly down from $2.07 in 2008. The move is aimed at conserving liquidity in the current credit-constrained market.
In response to the continued economic downturn and rapidly deteriorating industrial real-estate fundamentals, ProLogis had already stopped all new initiatives and early-stage developments. The company is currently concentrating on increasing its liquidity and deleveraging its balance sheet through asset sale.
ProLogis owns and manages interests in over 2,500 distribution facilities, service offices, and properties spanning 475 million square feet (including properties under development) of space. During the first quarter of 2009, the company sold its operations in China and Japan to affiliates of GIC Real Estate, the real-estate investment arm of the Government of Singapore Investment Corporation.
During the second quarter, ProLogis sold about 136 properties with an average age of 20 years. Spanning across 14.2 million square feet, the properties were located in markets like Chicago, Houston, Dallas, Atlanta, Memphis, Northern and Southern California, Seattle, Portland, Phoenix, Washington DC and Northern New Jersey.
ProLogis is the best-positioned industrial REIT in the current scenario. However, we maintain our Neutral recommendation on the stock in view of the overall decline of the industrial real estate sector.
@bbb... -
pass auf die Schweinegrippe auf , jedoch neu im Angebot:
05.08.2009 13:35
http://www.finanznachrichten.de/nachrichten-2009-08/14612245-novavax-achieves-pandemic-h1n1-influenza-production-milestone-cgmp-quality-material-produced-in-11-weeks-from-strain-availability-008.htm
NOVAVAX Achieves Pandemic H1N1 Influenza Production Milestone / cGMP quality material produced in 11 weeks from strain availability
ROCKVILLE, Md., Aug. 5 /PRNewswire-FirstCall/ -- Novavax, Inc. announced today it has manufactured a virus-like particle (VLP) vaccine candidate against the H1N1 pandemic influenza virus under current good-manufacturing practices (cGMP) at its new vaccine manufacturing facility in Rockville, MD. This milestone was accomplished in only 11 weeks after receiving the gene sequence for the H1N1 strain from the U.S. Centers for Disease Control. The Company was able to reach this manufacturing goal by employing proprietary, novel production technology which is not dependent on growing influenza virus in eggs. Chicken eggs are used to produce almost all of the world's influenza vaccine supply. In addition, Novavax has produced essential reagents for measuring vaccine potency. The Company also has plans to produce additional batches of the pandemic H1N1 VLP vaccine to support human clinical studies and stands ready to assist with additional public health needs in the US as well as foreign countries.
A detailed timeline describing the process from gene sequence to cGMP manufacturing is available on the Novavax website (http://www.novavax.com/).
Mr. Jim Robinson, Vice President of Manufacturing and Quality Operations at Novavax, commented, "Demonstration of our ability to construct and produce GMP-quality influenza vaccine within 12 weeks under real pandemic conditions is an important and successful test of our VLP technology. With further scale up, recombinant influenza VLP vaccine technology has the potential to expand vaccine surge capacity and significantly reduce the timeline for vaccine release. We are proud of our staff who worked tirelessly to achieve this important milestone while working concurrently to produce materials for a clinical study in the elderly population with our Seasonal Flu vaccine."
"The accomplishments announced today further validate our strategy to create a rapid, in-border influenza vaccine solution for governments around the world by addressing gaps in currently available vaccine technologies," added Dr. Rahul Singhvi, President and CEO of Novavax, Inc.
Novavax, Inc has successfully completed a Phase I/IIa clinical study with a candidate H5N1 influenza VLP vaccine and is currently in Phase II trials with a VLP based seasonal flu vaccine candidate. The Company plans to initiate a Phase II study with its Seasonal Flu vaccine candidate in the elderly population during Q4, 2009.
VG - Results, Chart & Short Interest
Vonage Holdings Corp. Reports Second Quarter 2009 Results
Date : 08/05/2009 @ 8:00AM
Source : PR Newswire
http://ih.advfn.com/p.php?pid=nmona&cb=1249477256&article=38914946&symbol=NY^VG
-- Adjusted EBITDA(1) Increases to $31 Million -- -- Vonage Reports GAAP Net Income of $2 Million or $0.01 per Share -- -- Generates Free Cash Flow of $12 Million --
HOLMDEL, N.J., Aug. 5 /PRNewswire-FirstCall/ -- Vonage Holdings Corp. (NYSE:VG), a leading provider of broadband telephone service, today announced results for the second quarter ended June 30, 2009.
Vonage reported record adjusted earnings before interest, taxes, depreciation and amortization ("EBITDA")(1) of $31 million, up from $12 million in the year ago quarter and $21 million sequentially. This is the seventh consecutive quarter of positive and increasing adjusted EBITDA and reflects the Company's continued focus on cost management and the deliberate reduction in marketing spend as it develops and launches its new marketing campaign and eliminates redundant spending.
Vonage reported positive income from operations of $15 million, up from a loss of $2 million the prior year and income of $5 million sequentially. Revenue of $220 million was down 3% year-over-year, and 2% sequentially.
For the first time ever, the Company generated net income of $1 million(2) or $0.01 per share excluding the benefit of a $1 million derivative liability adjustment related to the Company's convertible notes. This is an improvement from a loss(2) of $7 million or $0.04 in the second quarter of 2008. GAAP net income was $2 million or $0.01 per share.
Marc Lefar, Vonage Chief Executive Officer, said, "We generated record level adjusted EBITDA as well as increased free cash flow, underscoring our strong financial performance in the quarter. The cost reduction initiatives introduced over the last twelve months are generating important benefits for our company. We achieved a significant milestone, generating positive net income excluding adjustments for the first time in Company history."
"While our financial performance was strong, our subscriber base did not grow at expected levels due in part to the challenges of the current economy and the increasing impact of wireless substitution. During the quarter, we launched our new marketing campaign, which we anticipate will drive new customer acquisition over time. Over the coming weeks and months, we will roll out new products and plans that provide significant additional value to customers. These new products will capitalize on growth opportunities in both mobile and international markets while leveraging the technology that delivers Vonage services today."
...
http://www.shortsqueeze.com/?symbol=vg&submit=Short+Quote%99
Short Interest (Shares Short) 4,003,400
Days To Cover (Short Interest Ratio) 10.9
Short Percent of Float 5.04 %
Shares Float 79,480,000
Total Shares Outstanding 156,926,043
% Owned by Insiders 52.41 %
% Owned by Institutions 24.80 %
VG - Results, Chart & Short Interest
Vonage Holdings Corp. Reports Second Quarter 2009 Results
Date : 08/05/2009 @ 8:00AM
Source : PR Newswire
http://ih.advfn.com/p.php?pid=nmona&cb=1249477256&article=38914946&symbol=NY^VG
-- Adjusted EBITDA(1) Increases to $31 Million -- -- Vonage Reports GAAP Net Income of $2 Million or $0.01 per Share -- -- Generates Free Cash Flow of $12 Million --
HOLMDEL, N.J., Aug. 5 /PRNewswire-FirstCall/ -- Vonage Holdings Corp. (NYSE:VG), a leading provider of broadband telephone service, today announced results for the second quarter ended June 30, 2009.
Vonage reported record adjusted earnings before interest, taxes, depreciation and amortization ("EBITDA")(1) of $31 million, up from $12 million in the year ago quarter and $21 million sequentially. This is the seventh consecutive quarter of positive and increasing adjusted EBITDA and reflects the Company's continued focus on cost management and the deliberate reduction in marketing spend as it develops and launches its new marketing campaign and eliminates redundant spending.
Vonage reported positive income from operations of $15 million, up from a loss of $2 million the prior year and income of $5 million sequentially. Revenue of $220 million was down 3% year-over-year, and 2% sequentially.
For the first time ever, the Company generated net income of $1 million(2) or $0.01 per share excluding the benefit of a $1 million derivative liability adjustment related to the Company's convertible notes. This is an improvement from a loss(2) of $7 million or $0.04 in the second quarter of 2008. GAAP net income was $2 million or $0.01 per share.
Marc Lefar, Vonage Chief Executive Officer, said, "We generated record level adjusted EBITDA as well as increased free cash flow, underscoring our strong financial performance in the quarter. The cost reduction initiatives introduced over the last twelve months are generating important benefits for our company. We achieved a significant milestone, generating positive net income excluding adjustments for the first time in Company history."
"While our financial performance was strong, our subscriber base did not grow at expected levels due in part to the challenges of the current economy and the increasing impact of wireless substitution. During the quarter, we launched our new marketing campaign, which we anticipate will drive new customer acquisition over time. Over the coming weeks and months, we will roll out new products and plans that provide significant additional value to customers. These new products will capitalize on growth opportunities in both mobile and international markets while leveraging the technology that delivers Vonage services today."
...
http://www.shortsqueeze.com/?symbol=vg&submit=Short+Quote%99
Short Interest (Shares Short) 4,003,400
Days To Cover (Short Interest Ratio) 10.9
Short Percent of Float 5.04 %
Shares Float 79,480,000
Total Shares Outstanding 156,926,043
% Owned by Insiders 52.41 %
% Owned by Institutions 24.80 %
FDA Calendar Updates: Biomoda, Dynavax
Written by Mike Havrilla
Tuesday, 04 August 2009 12:47
http://biomedreports.com/articles/most-popular/4354-fda-calendar-updates-biomoda-dynavax.html
American Capital Announces Q2 2009 Results
05.08.2009 01:31
BETHESDA, Md., Aug. 4 /PRNewswire-FirstCall/ -- American Capital ("ACAS" or the "Company") announced net operating income ("NOI") for the quarter ended June 30, 2009 of $20 million, or $0.09 per diluted share. Earnings (loss) less appreciation and depreciation ("Realized (Loss) Earnings") for the quarter was $(306) million, or $(1.41) per diluted share. For the quarter ended June 30, 2009, the Company reported a net loss of $(547) million, or $(2.52) per diluted share.
Q2 2009 HIGHLIGHTS -- $1.07 per share dividend declared (in the aggregate 10% to be paid in cash and 90% in stock) -- $20 million of NOI -- $(308) million net realized loss on portfolio investments -- $125 million of realizations -- $8.76 net asset value ("NAV") per share -- $7.42 NAV per share adjusted for stock portion of accrued dividend payable and August 7, 2009 share dividend -- $12.83 anticipated realizable value upon settlement or maturity ("Realizable Value") per share -- $10.52 Realizable Value NAV per share adjusted for stock portion of accrued dividend payable and August 7, 2009 share dividend -- 44% reduction in workforce to date since March 31, 2008 NET OPERATING INCOME
NOI decreased 87% to $0.09 per diluted share for the quarter ended June 30, 2009, compared to $0.71 per diluted share for the prior year quarter. Relative to the first quarter of 2009, NOI in the second quarter was lower by $0.22 per diluted share primarily due to additional reversals of prior quarter accrued payment in kind ("PIK") interest and dividends (which are non-cash items) and increased interest costs related to default and rating downgrade provisions.
REALIZED (LOSS) EARNINGS
Realized (Loss) Earnings decreased to $(1.41) per diluted share for the quarter ended June 30, 2009, compared to $0.95 per diluted share for the prior year quarter. The Realized (Loss) Earnings for the quarter included a realized loss of $(196) million, or $(0.90) per diluted share, related to the sale of our portfolio company Consolidated Bedding, Inc.
NET LOSS
Net loss increased to $(2.52) per diluted share for the quarter ended June 30, 2009, compared to $(0.34) per diluted share for the prior year quarter.
For the quarter ended June 30, 2009, net unrealized depreciation of portfolio investments totaled $(311) million. The primary components of the net unrealized depreciation were as follows:
-- $315 million of reversals of prior depreciation associated with net realized losses on portfolio investments; -- $(409) million of depreciation of American Capital's investment in European Capital, Ltd., reflecting a significant discount to its NAV due to covenant defaults under European Capital's credit facilities, which could prevent realization of the NAV; -- $(289) million of net depreciation of American Capital's private finance portfolio; -- $35 million of appreciation of American Capital's investment in American Capital Agency Corp. and our portfolio company American Capital, LLC, an alternative asset fund manager; and -- $37 million of net appreciation from structured products. FINANCIAL HIGHLIGHTS
As of June 30, 2009, NAV per share was $8.76, down from $12.32 per share as of March 31, 2009 and $15.41 per share as of December 31, 2008. NAV per share was $7.42 as of June 30, 2009, when adjusted for the $207 million accrued dividend payable in stock and for the 67 million shares to be distributed on August 7, 2009. Based on Realizable Value, NAV per share was $12.83 as of June 30, 2009, down from $17.07 per share as of March 31, 2009 and $20.63 per share as of December 31, 2008. Realizable Value NAV per share was $10.52 as of June 30, 2009, when adjusted for the $207 million accrued dividend payable in stock and for the 67 million shares to be distributed on August 7, 2009.
"While we believe the broader economy has begun to recover in the second half of 2009, American Capital continues to face challenges," said Malon Wilkus, Chairman and Chief Executive Officer. "We remain focused on resolving the defaults with each of our unsecured creditor groups; providing operational, managerial and financial support to our portfolio companies; and improving operational efficiencies."
FINANCING UPDATE AND COVENANT BREACHES
The Company remains in default on $2.3 billion of unsecured credit arrangements outstanding as of June 30, 2009. The Company was able to reduce its outstanding securitized debt by $59 million during the quarter ended June 30, 2009. During the quarter ended June 30, 2009, the Company incurred expenses of $7 million related to its current debt restructuring efforts. In addition, the Company incurred $19 million during the quarter of interest expense as a result of default and rating agency downgrade provisions.
The Company continues to be below the 200% asset coverage ratio set forth in the Investment Company Act of 1940 and, as a result, the Company is generally restricted from issuing any new debt except to refinance existing debt. This does not restrict the use of cash from operations, allowing the reinvestment of proceeds from realizations of portfolio exits. The Company believes that it has sufficient liquidity to meet its currently scheduled debt amortization and the investment needs within its portfolio.
PORTFOLIO LIQUIDITY AND PERFORMANCE
In the second quarter of 2009, $125 million of proceeds were received from realizations of portfolio investment repayments and exits, which were 1% higher than the prior quarter's valuations of each investment. There was $39 million in new committed investments in the quarter. The weighted average effective interest rate on the Company's debt investments as of June 30, 2009, was 9.7%, 100 basis points lower than as of December 31, 2008. Cash and cash equivalents totaled $183 million as of June 30, 2009 and currently total approximately $300 million.
"While we expect to experience losses and depreciation during a severe recession," said John Erickson, Chief Financial Officer, "we continue to work hard to recover value from our underperforming companies. Our experience from the last recession leads us to believe that we will recover value in our portfolio companies as the economy strengthens. Despite having depreciation in some of our investments, we also have many fine investments such as People Media, where we generated a $15 million gain, a 30% annual return and $57 million in cash proceeds in July on our investment, despite one of the worst environments for middle market M&A. With our large and diverse portfolio, we continue to generate liquidity despite the poor M&A environment, as evidenced by the $125 million of proceeds during the second quarter. That trend continued in July, as we sold over $100 million of investments at approximately their fair value. We believe the worst is behind us."
As of June 30, 2009, loans with a fair value of $310 million were on non-accrual. The $310 million fair value of non-accruing loans represented 7.2% of total loans at fair value as of June 30, 2009, compared to the $214 million fair value of non-accrual loans representing 4.4% of total loans at fair value as of March 31, 2009.
2009 DIVIDENDS
On July 31, 2009, American Capital announced the results of its stockholders' elections relating to the Company's dividend previously declared by its Board of Directors on June 11, 2009. The dividend of $1.07 per share is payable on August 7, 2009 to stockholders of record as of the close of business on June 22, 2009, with an ex-dividend date of June 18, 2009. Stockholders had until July 24, 2009 to elect whether to receive the dividend in cash (up to an aggregate maximum of 10% of the total dividend paid) or in shares of common stock. Due to the original terms of the dividend, stockholders who elected to receive cash will receive a combination of cash and common stock.
Based on stockholder elections and the price of American Capital's common stock, the dividend will consist of approximately $24 million in cash and approximately 67 million shares of common stock. The amount of cash elected to be received was greater than the cash limit of 10% of the aggregate dividend amount, and therefore stockholders who elected to receive all cash will receive a combination of cash and stock. Stockholders electing to receive the dividend in all cash, will receive cash in the amount of $0.185 per share or 17% of the $1.07 dividend and 0.275 shares of common stock or 83% of the total dividend for each share of common stock they owned on the record date. The number of shares of common stock comprising the stock portion was calculated based on a price of $3.2199 per share, the average of the volume weighted trading price per share on the NASDAQ Global Select Market on July 27, 28 and 29, 2009.
...
Sequenom Earnings Conference Call (Q2 2009)
Scheduled to start Thu, Aug 6, 2009, 4:30 pm Eastern
http://biz.yahoo.com/cc/9/106539.html
Wall Street's Buy List
By Rich Smith (TMF Ditty)
August 4, 2009
http://www.fool.com/investing/value/2009/08/04/wall-streets-buy-list.aspx
KERX - Chart
CENX - Chart & Short Interest
http://www.shortsqueeze.com/?symbol=cenx&submit=Short+Quote%99
Short Interest (Shares Short) 12,987,100
Days To Cover (Short Interest Ratio) 2.6
Short Percent of Float 28.80 %
Shares Float 45,100,000
Total Shares Outstanding 74,139,488
% Owned by Insiders 38.69 %
% Owned by Institutions 48.20 %
CENX -
Century Aluminum Divests Stakes in Bauxite and Alumina Assets
Date : 08/04/2009 @ 9:30AM
Source : MarketWire
http://ih.advfn.com/p.php?pid=nmona&cb=1249403596&article=38897151&symbol=N^CENX
MONTEREY, CA -- (Marketwire) -- 08/04/09 -- Century Aluminum Company (NASDAQ: CENX) today announced it has reached an agreement to transfer the company's 50% ownership interests in Gramercy Alumina LLC and St. Ann Bauxite Limited to certain subsidiaries of Noranda Aluminum Holding Corporation (together with its consolidated subsidiaries, "Noranda"). Century will make modest cash payments to Gramercy as part of the transaction, which is expected to close in August. At close, Noranda will assume 100% ownership of Gramercy and St.
Ann.
Century's primary aluminum smelter in Hawesville, KY currently receives all of its alumina supplies from Gramercy. Century and Noranda will also enter in an agreement under which Century will purchase alumina from Gramercy for a limited period of time.
Century and Noranda jointly acquired Gramercy and St. Ann from Kaiser Aluminum and Chemical Corp. in 2004 and have each owned 50 percent of these businesses since that time. Gramercy owns and operates a 1.2 million metric ton per year alumina annual capacity alumina refinery located in Louisiana and St. Ann owns and operates a 4.8 million metric ton per year annual capacity bauxite mining operation in Jamaica. As a result of the economic crisis, Gramercy and St. Ann have been producing at approximately 50 percent and 40 percent of their rated capacities since early 2009.
"Our five-year association with Noranda, Gramercy and St. Ann has been mutually beneficial, and we have enjoyed working with the outstanding teams that manage these businesses," said Century executive vice president and chief operating officer Wayne R. Hale. "This transaction will increase our focus on Century's core aluminum smelting business and our attractive growth projects. In addition, the full curtailment of Ravenswood and partial curtailment of Hawesville have reduced our alumina requirements. We have attractive contracts in place which will supply our alumina needs over the next several years."
Century Aluminum Company owns primary aluminum capacity in the United States and Iceland. Century's corporate offices are located in Monterey, California.
Big drugmakers start trials of swine flu vaccines
Written by Reuters
Tuesday, 04 August 2009 08:13
http://biomedreports.com/articles/most-popular/4290-big-drugmakers-start-trials-of-swine-flu-vaccines.html
Century Aluminum Divests Stakes in Bauxite and Alumina Assets
Date : 08/04/2009 @ 9:30AM
Source : MarketWire
http://ih.advfn.com/p.php?pid=nmona&cb=1249394457&article=38897151&symbol=N^CENX
SQNM - Chart & Short Interest
http://www.shortsqueeze.com/?symbol=sqnm&submit=Short+Quote%99
Short Interest (Shares Short) 19,391,700
Days To Cover (Short Interest Ratio) 3.4
Short Percent of Float 42.16 %
Short Interest - Prior 15,979,700
Shares Float 46,000,000
Total Shares Outstanding 61,134,052
GCI - Chart & Short Interest
http://www.shortsqueeze.com/?symbol=gci&submit=Short+Quote%99
Short Interest (Shares Short) 39,095,700
Days To Cover (Short Interest Ratio) 6.2
Short Percent of Float 16.96 %
Short Interest - Prior 38,350,300
Shares Float 230,550,000
Total Shares Outstanding 234,751,324
% Owned by Insiders 0.52 %
% Owned by Institutions 99.00 %
Customers Report Positive Results with Converted Organics’ Fertilizers
Date : 08/04/2009 @ 9:00AM
Source : Business Wire
http://ih.advfn.com/p.php?pid=nmona&cb=1249391791&article=38896444&symbol=N^COIN
Keryx Biopharmaceuticals Settles License Dispute With Alfa Wassermann
Date : 08/04/2009 @ 8:30AM
Source : PR Newswire
http://ih.advfn.com/p.php?pid=nmona&cb=1249391791&article=38895758&symbol=N^KERX